Exelixis
EXEL
#1566
Rank
ยฃ8.63 B
Marketcap
ยฃ30.85
Share price
1.24%
Change (1 day)
73.15%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) Fails to deliver data

Key failure to deliver metrics for Exelixis:

A Failure to deliver also known as fails-to-deliver or FTD occurs when a buyer or seller is unable to meet his trading obligations. FTDs for US listed companies are reported to the SEC and published twice a month. Therefore there is a certain delay between the reporting and the publishing of the data.

Failures to deliver for Exelixis (EXEL) - 3 months history

Number of shares, 3 months chart

Biweekly Failures to deliver volume for Exelixis (EXEL) - since 2013

Volume in USD (price x number of shares), data since 2013

Exelixis (EXEL) Failure to deliver volume, Year over Year

Year Volume (Price x Shares) Change
2025ยฃ1.76 M-85.42%
2024ยฃ12.08 M86.29%
2023ยฃ6.48 M-41.81%
2022ยฃ11.14 M-31.9%
2021ยฃ16.36 M-20.71%
2020ยฃ20.64 M303.63%
2019ยฃ5.11 M-70.5%
2018ยฃ17.33 M8.82%
2017ยฃ15.92 M-17.35%
2016ยฃ19.27 M-75.68%
2015ยฃ79.23 M19.37%
2014ยฃ66.37 M258.49%
2013ยฃ18.51 M

FTD volume in the last 3 months for similar companies or competitors

Company FTD volume (3 months) FTD volume (1 year) Country
ยฃ81.01 Mยฃ0.17 B๐Ÿ‡ฌ๐Ÿ‡ง UK
ยฃ1.21 Mยฃ47.51 M๐Ÿ‡ซ๐Ÿ‡ท France
ยฃ80.49 Mยฃ0.13 B๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ0.16 Bยฃ0.47 B๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ37.38 Mยฃ0.21 B๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ15.09 Mยฃ0.22 B๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ24.22 Mยฃ0.33 B๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ0.04 Mยฃ0.84 M๐Ÿ‡บ๐Ÿ‡ธ USA
N/Aยฃ0.04 M๐Ÿ‡บ๐Ÿ‡ธ USA